This federal contract award, valued at $1,182.96, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with an ultimate completion date of October 17, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type. This award is not associated with a set-aside designation, indicating open competition. AmerisourceBergen, the prime contractor, has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
Generated 1/15/25, 9:20 AM